Repotrectinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 40mg, 160mg
Reference Brands: Augtyro (USA)
Category:
Oncology Cancer Care
Repotrectinib is a targeted cancer therapy used to treat ROS1-positive non-small cell lung cancer (NSCLC) and NTRK fusion-positive solid tumors. It works as a tyrosine kinase inhibitor, blocking key enzymes that promote tumor growth and survival. Available as oral capsules in strengths of 40 mg and 160 mg, Repotrectinib is designed for patients with advanced or metastatic cancers who have limited treatment options.
Repotrectinib is available in Capsules
and strengths such as 40mg, 160mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Repotrectinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Repotrectinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing